Effect of a monoclonal antibody to sclerostin (romosozumab) on dialysis patients with osteoporosis
Latest Information Update: 03 Jun 2022
At a glance
- Drugs Romosozumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 02 Jun 2022 Planned End Date changed from 31 Mar 2024 to 31 Dec 2024.
- 02 Mar 2022 Planned End Date changed from 31 Dec 2024 to 31 Mar 2024.
- 28 Aug 2021 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.